Cargando…

Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer

PURPOSE: This study investigated the efficacy and toxicity associated with consolidation chemotherapy using paclitaxel and carboplatin after concurrent chemoradiation (CCR) in cervical cancer patients. MATERIALS AND METHODS: From a total of 37 patients, 19 with International Federation of Gynecology...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hee Seung, Kim, Mi-Kyung, Kim, Hak Jae, Han, Seung-Su, Kim, Jae Weon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394869/
https://www.ncbi.nlm.nih.gov/pubmed/22802747
http://dx.doi.org/10.4143/crt.2012.44.2.97
_version_ 1782237906216157184
author Kim, Hee Seung
Kim, Mi-Kyung
Kim, Hak Jae
Han, Seung-Su
Kim, Jae Weon
author_facet Kim, Hee Seung
Kim, Mi-Kyung
Kim, Hak Jae
Han, Seung-Su
Kim, Jae Weon
author_sort Kim, Hee Seung
collection PubMed
description PURPOSE: This study investigated the efficacy and toxicity associated with consolidation chemotherapy using paclitaxel and carboplatin after concurrent chemoradiation (CCR) in cervical cancer patients. MATERIALS AND METHODS: From a total of 37 patients, 19 with International Federation of Gynecology and Obstetrics (FIGO) stage IB1-IIA cervical cancer (group 1) underwent surgery followed by consolidation chemotherapy after CCR, and 18 with stage IIB-IVA disease (group 2) received consolidation chemotherapy after primary CCR. Three cycles of chemotherapy using paclitaxel (135 mg/m(2)) and carboplatin (AUC 5.0) were administered every 3 weeks for CCR therapy, and three cycles of consolidation chemotherapy using paclitaxel (175 mg/m(2)) and carboplatin (AUC 5.0) were used every 3 weeks after CCR. RESULTS: The complete and partial response rates were 77.8% and 22.2% in group 2. Moreover, the 3-year progression-free and overall survival rates were 62.7% and 90.9% in group 1, and 51.9% and 60% in group 2, respectively. The most common grade 3 or 4 hematologic toxicities observed were leukopenia (group 1, 10.5%; group 2, 13.0%) and neutropenia (group 1, 7.0%; group 2, 14.8%), and grade 3 or 4 diarrhea (group 1, 1.8%) and febrile illness (group 2, 1.9%) were the most frequently observed non-hematologic toxicities. When we compared these results with previous reports, consolidation chemotherapy after CCR using paclitaxel and carboplatin revealed a relatively lower complete response rate (77.8% vs. 87-100%, respectively) and shorter progression-free survival (51.9-62.7% vs. 81-86%, respectively) and overall survival (60-90.9% vs. 81-95%, respectively) in spite of similar toxicity findings. CONCLUSION: Due to low efficacy results, consolidation chemotherapy using paclitaxel and carboplatin after CCR is not a feasible treatment regimen for high-risk early-stage or locally advanced cervical cancer.
format Online
Article
Text
id pubmed-3394869
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Korean Cancer Association
record_format MEDLINE/PubMed
spelling pubmed-33948692012-07-16 Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer Kim, Hee Seung Kim, Mi-Kyung Kim, Hak Jae Han, Seung-Su Kim, Jae Weon Cancer Res Treat Original Article PURPOSE: This study investigated the efficacy and toxicity associated with consolidation chemotherapy using paclitaxel and carboplatin after concurrent chemoradiation (CCR) in cervical cancer patients. MATERIALS AND METHODS: From a total of 37 patients, 19 with International Federation of Gynecology and Obstetrics (FIGO) stage IB1-IIA cervical cancer (group 1) underwent surgery followed by consolidation chemotherapy after CCR, and 18 with stage IIB-IVA disease (group 2) received consolidation chemotherapy after primary CCR. Three cycles of chemotherapy using paclitaxel (135 mg/m(2)) and carboplatin (AUC 5.0) were administered every 3 weeks for CCR therapy, and three cycles of consolidation chemotherapy using paclitaxel (175 mg/m(2)) and carboplatin (AUC 5.0) were used every 3 weeks after CCR. RESULTS: The complete and partial response rates were 77.8% and 22.2% in group 2. Moreover, the 3-year progression-free and overall survival rates were 62.7% and 90.9% in group 1, and 51.9% and 60% in group 2, respectively. The most common grade 3 or 4 hematologic toxicities observed were leukopenia (group 1, 10.5%; group 2, 13.0%) and neutropenia (group 1, 7.0%; group 2, 14.8%), and grade 3 or 4 diarrhea (group 1, 1.8%) and febrile illness (group 2, 1.9%) were the most frequently observed non-hematologic toxicities. When we compared these results with previous reports, consolidation chemotherapy after CCR using paclitaxel and carboplatin revealed a relatively lower complete response rate (77.8% vs. 87-100%, respectively) and shorter progression-free survival (51.9-62.7% vs. 81-86%, respectively) and overall survival (60-90.9% vs. 81-95%, respectively) in spite of similar toxicity findings. CONCLUSION: Due to low efficacy results, consolidation chemotherapy using paclitaxel and carboplatin after CCR is not a feasible treatment regimen for high-risk early-stage or locally advanced cervical cancer. Korean Cancer Association 2012-06 2012-06-30 /pmc/articles/PMC3394869/ /pubmed/22802747 http://dx.doi.org/10.4143/crt.2012.44.2.97 Text en Copyright © 2012 by the Korean Cancer Association http://creativecommons.org/licenses/by-nc/3.0 This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kim, Hee Seung
Kim, Mi-Kyung
Kim, Hak Jae
Han, Seung-Su
Kim, Jae Weon
Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer
title Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer
title_full Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer
title_fullStr Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer
title_full_unstemmed Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer
title_short Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer
title_sort phase ii study of consolidation chemotherapy after adjuvant or primary concurrent chemoradiation using paclitaxel and carboplatin to treat high-risk early-stage or locally advanced cervical cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394869/
https://www.ncbi.nlm.nih.gov/pubmed/22802747
http://dx.doi.org/10.4143/crt.2012.44.2.97
work_keys_str_mv AT kimheeseung phaseiistudyofconsolidationchemotherapyafteradjuvantorprimaryconcurrentchemoradiationusingpaclitaxelandcarboplatintotreathighriskearlystageorlocallyadvancedcervicalcancer
AT kimmikyung phaseiistudyofconsolidationchemotherapyafteradjuvantorprimaryconcurrentchemoradiationusingpaclitaxelandcarboplatintotreathighriskearlystageorlocallyadvancedcervicalcancer
AT kimhakjae phaseiistudyofconsolidationchemotherapyafteradjuvantorprimaryconcurrentchemoradiationusingpaclitaxelandcarboplatintotreathighriskearlystageorlocallyadvancedcervicalcancer
AT hanseungsu phaseiistudyofconsolidationchemotherapyafteradjuvantorprimaryconcurrentchemoradiationusingpaclitaxelandcarboplatintotreathighriskearlystageorlocallyadvancedcervicalcancer
AT kimjaeweon phaseiistudyofconsolidationchemotherapyafteradjuvantorprimaryconcurrentchemoradiationusingpaclitaxelandcarboplatintotreathighriskearlystageorlocallyadvancedcervicalcancer